An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-Arm Phase 1b Study in Patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY)
A study for patients with muscle invasive bladder cancer (MIBC) using study drugs MEDI4736 and AZD4547
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAQ4008
U.S. Govt. ID: NCT02546661
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: This research study is designed to determine whether the study drugs are effective in treating muscle invasive bladder cancer in patients whose cancer did not stop, or whose cancer returned after being treated with other drugs, and study what kind of side effects are caused by these study drugs. To do this, a group of patients will be given MEDI4736 in combination with AZD4547, and compared with another group who will receive AZD4547 alone.
This study is closed
Emerson Lim, MD
Do You Qualify?
Have you been diagnosed with bladder cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator